Research
At the Dubin Breast Center, we provide excellence in all facets of breast cancer care. In addition, our mission includes tirelessly pursuing better outcomes for breast cancer patients. By housing multiple clinical services under one roof, we foster interdisciplinary and translational research to help achieve this goal. The Dubin Breast Center and Tisch Cancer Institute faculty members have a wide range of breast cancer research projects, including the following:
- Providing a high-risk surveillance program for individuals at high risk for developing breast cancer
- Identifying the causes of breast cancer
- Studying the reasons for disparities in breast cancer treatment
- Finding novel approaches to treating breast cancer
- Understanding breast cancer dormancy
- Exploring new ways to prevent and diagnose breast cancer
- Evaluating the safety and efficacy of new and existing breast cancer treatments through clinical trials
How to Participate in Research
When you participate in a clinical trial, you help yourself—and everyone else. Being part of a clinical trial gives you a chance to receive a new treatment that might otherwise be unavailable to you. It also helps us work to improve the standard of care for current and future breast cancer patients. The Dubin Center does not do research on its own. Our doctors work closely with partners in the pharmaceutical industry in our research efforts. We also work with cooperative groups through the National Cancer Institute such as Alliance for Clinical Trials in Oncology, Cancer and Leukemia Group B, and the American College of Radiology Imaging Network.
Open Clinical Trials at the Dubin Breast Center
We are always involved in numerous studies to examine breast cancer imaging, genetics, radiation, chemotherapy, surgery, prevention, and treatment disparities. Speak with your Dubin health care team if you have questions about or interest in any of our current clinical trials. Often, clinical trials have specific criteria that you must meet to participate.
Ductal Carcinoma in Situ (DCIS) Trials
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low-Risk DCIS (COMET)
-
Contact: Kereeti V. Pisapati, MS; (212) 241-2475
Pre-Surgery Treatment Trials (Neoadjuvant)
Patient-Derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
-
Contact: Kereeti V. Pisapati, MS; (212) 241-2475
-
Contact: Kereeti V. Pisapati, MS; (212) 241-2475
-
Contact: Ronald Couri; (212) 241-6308
-
Contact: Gargi Joshi, MS; (212) 824-7320
Post-Surgery Treatment Trials (Adjuvant)
Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence
-
Contact: Andrea Lopez, MPH (212) 659-5557
Treating Cancer-Related Fatigue Through Systemic Light Exposure (Light for Fatigue Study)
-
Contact: Christopher Hickson; (212) 824-7193
-
Contact: Christopher Hickson; (212) 824-7193
-
Contact: Gargi Joshi, MS; (212) 824-7320
-
Contact: Gargi Joshi, MS; (212) 824-7320
-
Contact: Gargi Joshi, MS; (212) 824-7320
Phase 3 Study of Sacituzumab Govitecan (IMMU-132) versus Treatment of Physician's Choice (TPC) in Subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens for Metastatic Disease
· Contact: Annie Gevertz; (212) 824-7351
Metastatic Breast Cancer (MBC) Trials
-
Contact: Christopher Hickson; (212) 824-7193
-
Contact: Annie Gevertz; (212) 824-7351
-
Contact: Christopher Hickson; (212) 824-7193
-
Contact: Gargi Joshi, MS; (212) 824-7320
-
Contact: Annie Gevertz; (212) 824-7351
-
Contact: Gargi Joshi, MS; (212) 824-7320
Ductal Carcinoma in Situ (DCIS) Trials
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS (COMET)
- Contact: Kereeti V. Pisapati, MS; (212) 241-2475
Pre-Surgery Treatment Trials (Neoadjuvant)
Patient-Derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
- Contact: Kereeti V. Pisapati, MS; (212) 241-2475
- Contact: Kereeti V. Pisapati, MS; (212) 241-2475
- Contact: Ronald Couri; (212) 241-6308
- Contact: Wenjie Wang; (212) 824-7193 or Umar Farooq; (212) 824-7876
- Contact: Wenjie Wang; (212) 824-7193 or Umar Farooq; (212) 824-7876
Post-Surgery Treatment Trials (Adjuvant)
Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence
- Contact: Integrative Behavioral Medicine Program team; (212) 659-5521
Treating Cancer-Related Fatigue Through Systemic Light Exposure (Light for Fatigue Study)
- Contact: Kathryn Sommer; (212) 659-5645 or Julia Granski; (212) 659-5547
- Contact: Wenjie Wang; (212) 824-7193 or Umar Farooq; (212) 824-7876
- Contact: Wenjie Wang; (212) 824-7193 or Umar Farooq; (212) 824-7876
- Contact: Wenjie Wang; (212) 824-7193 or Umar Farooq; (212) 824-7876
Immunotherapy Trials
- Contact: Wenjie Wang; (212) 824-7193 or Umar Farooq; (212) 824-7876
- Contact: Wenjie Wang; (212) 824-7193 or Umar Farooq; (212) 824-7876
Metastatic Breast Cancer (MBC) Trials
- Contact: Wenjie Wang; (212) 824-7193 or Umar Farooq; (212) 824-7876
- Contact: Wenjie Wang; (212) 824-7193 or Umar Farooq; (212) 824-7876
- Contact: Wenjie Wang; (212) 824-7193 or Umar Farooq; (212) 824-7876
- Contact: Wenjie Wang; (212) 824-7193 or Umar Farooq; (212) 824-7876